1. Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker RC, Perhach JL, Affrime MB, Glue P. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit. 1996;18:19–29.
2. Binelli S, Canafoglia L, Mamoli D, Avanzini G, Guidolin L, Canger R, Politini L, Sartori I, Tartara A, Perucca E, Giubergia S, Mazzari P, Zagnoni P, Garofalo P, Durisotti C, Ricci S, Manfredi M, Mainardi F, Paladin F, Michelucci R, Tassinari CA, Sasso E, Mancia D, Zaccara G, Mascia V, Marrosu F, Nocerino C, Striano S, Spinelli A, Specchio LM, Russo M, Alagna A, Pisani F, Di Perri R, Raspanti G, Daniele O, Bettini B, Zibetti A, Montanini R, Lunardi G. Felbamate as add-on therapy in adult patients with partial drug-resistant epilepsy. Bollettino Lega Italiana Contro L’Epilessia. 1999;106–107:317–8.
3. Bourgeois BF. Felbamate in the treatment of partial-onset seizures. Epilepsia. 1994;35(Suppl 5):S58–61.
4. Bourgeois B, Leppik IE, Sackellares JC, Laxer K, Lesser R, Messenheimer JA, Kramer LD, Kamin M, Rosenberg A. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology. 1993;43:693–6.
5. Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol. 1994;17:389–402.